Patients


About Generic Drugs

Generic medicines are authorised to the same standards of safety, quality and efficacy as original branded drugs. They contain the same active pharmaceutical ingredient and have to demonstrate that they provide the same medical benefits to the patient (i.e. are therapeutically equivalent to the original product). Typically, generic medicines are interchangeable with the equivalent, original branded drug.1

  • The active pharmaceutical ingredient is the same as that of the original branded drug<sup>1</sup>
  • The generic medicine acts in the same way in the patient’s body and is interchangeable with the branded drug<sup>1</sup>
  • Although there may be some differences between the generic medicine and the original drug, such as the colour or inactive ingredients, these are acceptable as they do not impact on how the medicine works<sup>1</sup>
  • Generic medicines must comply with the same strict standards as the branded drug<sup>1</sup>
  • The medicine has a similar route of administration (such as oral or topical)
  • The indication for use usually matches the branded drug
  • The container in which the medicine will be shipped and sold is appropriate
  • Relevant patents or exclusivities are appropriately addressed
  • The use of generic medicines supports the NHS by reducing the cost of the NHS annual medicines bill<sup>1,2</sup>

To learn even more about generic drugs, please visit: www.britishgenerics.co.uk/

Report Adverse Events

Glenmark is committed to patient safety. Our Global Drug Safety Risk Management function monitors, assesses and reports on the safety of our medicines throughout the products’ lifecycles, from discovery and research to post-approval, when they become available to patients.

Glenmark has established a systematic process for collecting, analysing and reporting safety information in order to optimise patient safety in compliance with local and global guidance regulations.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Suspected adverse reactions can be reported via the Yellow Card Scheme at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Glenmark can also be contacted to report suspected adverse reactions on 0800 458 0383 or at medical_information@glenmarkpharma.com.
To ask any questions about Glenmark products in the United Kingdom, please contact Glenmark Medical Information at medical_information@glenmarkpharma.com.

References

  1. BGMA. About generics. Available at https://www.britishgenerics.co.uk/about-generics.html. Accessed March 2021.
  2. NHS. NHS cuts medicines costs by three quarters of a billion pounds. 31 August 2019. Available at https://www.england.nhs.uk/2019/08/nhs-cuts-medicines-costs-by-three-quarters-of-a-billion-pounds/. Accessed March 2021.